Safety of Taking Ubrelvy After Toradol Injection
Yes, it is safe to take ubrogepant (Ubrelvy) after receiving a ketorolac (Toradol) injection - there are no known drug interactions between these medications.
Key Evidence
The FDA drug label for Ubrelvy explicitly states that no significant pharmacokinetic interactions were observed when ubrogepant was administered with naproxen 1, another NSAID in the same class as ketorolac. This provides direct evidence that NSAIDs do not interfere with ubrogepant's metabolism or safety profile.
Why This Combination is Safe
No Metabolic Interactions
- Ubrogepant is primarily metabolized by CYP3A4 and is a substrate of P-gp and BCRP transporters 1
- Ketorolac does not significantly affect CYP3A4 activity or these transporters
- The FDA label lists specific medications requiring dose adjustments (strong CYP3A4 inhibitors like ketoconazole, clarithromycin, itraconazole), and ketorolac is notably absent 1
Complementary Mechanisms
- Ketorolac works through COX inhibition (reducing prostaglandin-mediated inflammation)
- Ubrogepant blocks CGRP receptors (interrupting migraine-specific pain pathways) 2
- These distinct mechanisms mean no overlapping toxicity concerns
Clinical Context from Guidelines
The 2025 American College of Physicians guideline recommends a stepwise approach to migraine treatment 3:
- Start with NSAIDs (like ketorolac) or acetaminophen
- Add a triptan if NSAIDs provide insufficient relief
- Consider gepants (including ubrogepant) for patients who don't respond to or tolerate triptan combinations
The 2024 VA/DoD guideline gives ubrogepant a "weak for" recommendation for acute migraine treatment 4, with an NNT of 12 for pain freedom at 2 hours 5.
Practical Considerations
Timing
- You can take Ubrelvy immediately after a Toradol injection or at any interval
- No waiting period is required between medications
What to Monitor
- Hypersensitivity reactions: Ubrelvy can rarely cause allergic reactions (swelling, difficulty breathing) 1
- Blood pressure: Ubrelvy may increase blood pressure or worsen pre-existing hypertension 1
- Raynaud's phenomenon: Watch for circulation problems in fingers/toes 1
Common Pitfall to Avoid
Do not confuse this with strong CYP3A4 inhibitors, which ARE contraindicated with Ubrelvy. Ketorolac is NOT a CYP3A4 inhibitor - it's simply an NSAID with anti-inflammatory properties.
Safety Profile
Long-term safety data from a 52-week trial showed ubrogepant was well-tolerated with treatment-related adverse events in only 10-11% of patients 6. The most common side effects are nausea, somnolence, and dry mouth (occurring in <5% of patients) 7.
The combination of ketorolac and ubrogepant carries no additional risk beyond the individual safety profiles of each medication.